Recovery · Reference
ARA-290 for Women: What the Research Has Looked At, and What It Is Not
This page covers what ARA-290 is, what research has and has not looked at, the questions that change for women (pregnancy, breastfeeding, conception, hormone therapy), what to rule out first, and how Pepti supplies it. The general reference is what is ARA-290, and the trial-by-trial detail is in ARA-290 benefits.
ARA-290 has not been studied in women specifically: its randomised phase 2 trials enrolled adults with sarcoidosis-associated small-fibre neuropathy or type 2 diabetes with painful neuropathy, and none in the live research reports results separately for women. Those trials reported improved neuropathy symptom questionnaires and increased corneal nerve fibre density after four weeks, with no safety concerns, but pain-intensity scores did not clearly separate from placebo. ARA-290 is not used in pregnancy or while breastfeeding, because safety data is absent. Burning, tingling or numbness has testable causes, including B12 deficiency, thyroid disease and glucose, that are worth checking first. It is a compounded prescription injection and is not FDA approved.
This page covers what ARA-290 is, what research has and has not looked at, the questions that change for women (pregnancy, breastfeeding, conception, hormone therapy), what to rule out first, and how Pepti supplies it. The general reference is what is ARA-290, and the trial-by-trial detail is in ARA-290 benefits.
ARA-290 for Women
The short answer
| Question | What the live research shows | Strength of evidence |
|---|---|---|
| Has it been studied in women specifically? | No trial in the live research reports women separately | None |
| Small-fibre neuropathy in sarcoidosis | Trials in 2012, 2013 and 2017 (up to 64 people) | Human, small, short, developer-run |
| Painful neuropathy in type 2 diabetes | One 2015 phase 2 trial, 28 days | Human, small, not replicated |
| Pregnancy or breastfeeding | Not used; safety data is absent | No data |
| Trying to conceive | Nothing in the live research | No data |
| Does it act on hormones or the cycle? | It is not a hormone and not described to act on any hormone axis | Not described |
| Alongside hormone therapy or contraception | No study of the combination | None |
| Diabetic macular oedema | A 2020 study of nine people found no improvement | Human, negative |
ARA-290 for Women
What ARA-290 is, in one paragraph
ARA-290, also called cibinetide and in older papers helix B surface peptide, is an eleven-amino-acid peptide whose sequence was taken from one helix of erythropoietin, the kidney hormone that tells bone marrow to make red blood cells. It was engineered so that it does not bind the receptor pair that drives red cell production, so it does not raise haemoglobin. It is described instead as engaging the innate repair receptor, one erythropoietin receptor paired with the beta-common receptor (CD131), described as switched on in injured or inflamed tissue. Animal work describes it damping inflammatory signalling in nerve tissue. It is not a painkiller, not a hormone and not a weight medication.
ARA-290 for Women
What research has looked at
| Trial | Who | Length | What it reported |
|---|---|---|---|
| Molecular Medicine, 2012, pilot | 22 people with sarcoidosis and small-fibre neuropathy symptoms | Four weeks, intravenous | Symptom questionnaire improved more than placebo; pain score and fatigue improved equally in both groups; depressive symptoms did not change |
| Molecular Medicine, 2013 | People with sarcoidosis and documented small nerve fibre loss | 28 days, daily subcutaneous | Symptoms improved; corneal nerve fibre density increased |
| Molecular Medicine, 2015 | People with type 2 diabetes and painful neuropathy | 28 days, daily subcutaneous | PainDetect scores improved; HbA1c and lipids improved against placebo |
| Investigative Ophthalmology and Visual Science, 2017 | 64 people with sarcoidosis-associated nerve fibre loss | 28 days | Only the middle dose beat placebo on corneal nerve fibre area |
| Journal of Clinical Medicine, 2020 | 9 people with diabetic macular oedema | Twelve weeks | No improvement in vision or retinal thickness; safe; no antibodies |
| European Neuropsychopharmacology, 2015 | 36 healthy volunteers | A single dose | No effect on mood |
What it shows. A consistent signal on small nerve fibre regrowth and neuropathy symptom questionnaires in two specific patient groups, and a clean safety record over short courses.
What it does not show. Any result reported by sex, any benefit in healthy women, an effect on pain intensity clearly beyond placebo, or anything beyond four weeks of treatment. The single-dose study found no effect on mood, so it is not a mood treatment either.
ARA-290 for Women
What changes for women
Pregnancy and breastfeeding
ARA-290 is not used in pregnancy or while breastfeeding: safety data is absent. If you become pregnant while taking it, or are planning a pregnancy, message your care team through your account. The wider picture is in can you take peptides while pregnant.
Trying to conceive
Nothing in the live research looks at ARA-290 and fertility in either direction. If conception is a goal, raise it with your physician before starting. See do peptides affect fertility.
Hormones, the cycle and contraception
ARA-290 is not a hormone and is not described to act on oestrogen, progesterone, the pituitary or the menstrual cycle. No study has looked at it alongside hormonal contraception or menopausal hormone therapy, and no interaction is described, but it has no established interaction list at all. List every hormone product on your intake. Menopause questions in general are in peptides for menopause.
It is not erythropoietin
Because ARA-290 is built from part of erythropoietin, a natural question, for anyone with heavy periods or low iron, is whether it raises blood counts. It does not: it was engineered not to, and the trials confirmed no effect on red cell production. It is not a treatment for anaemia.
Diabetes and glucose-lowering medication
The 2015 trial reported improved HbA1c against placebo, so anyone on insulin or other glucose-lowering medication should tell their physician. That is a precaution drawn from trial data, not an established interaction. If you also take a GLP-1, see can you take ARA-290 with tirzepatide.
ARA-290 for Women
What to rule out first
Burning, tingling or numbness in the hands and feet has causes that can be tested for, and they come before a peptide.
| Possible cause | How it can show up | Why it comes first |
|---|---|---|
| B12 deficiency | Tingling, numbness, fatigue | Findable and directly treatable; methylcobalamin is the more direct conversation |
| Thyroid disease | Fatigue, weight change, cold intolerance | Common, findable, not treated by a peptide |
| Poorly controlled glucose | Burning or numb feet, thirst | Glucose control is the foundation of diabetic neuropathy care |
| Inflammation without nerve damage | A broader inflammatory picture | KPV is generally the more direct discussion |
Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. A broader overview is in peptides for women.
ARA-290 for Women
What the evidence does not establish
- It does not establish any difference between how women and men respond, because no trial reported results by sex.
- It does not establish that ARA-290 reduces pain intensity more than placebo.
- It does not establish benefit in neuropathy from other causes, such as chemotherapy, alcohol or injury, because those groups were not studied.
- It does not establish what happens beyond four weeks of treatment, or with repeated courses.
- It does not establish safety in pregnancy or breastfeeding.
ARA-290 for Women
Side effects
Nothing in the live research suggests the profile differs between women and men.
| What is reported or relevant | When | What to do |
|---|---|---|
| Injection-site redness, mild soreness, occasional bruising | Any time | Rotate sites between abdomen and thigh |
| Signs that could be low blood sugar, if you take glucose-lowering medication | Any time | Treat it first, then tell your care team |
| Pregnancy, or planning one | Any time | Message your care team |
| Facial or throat swelling, trouble breathing, widespread rash | Rare | Call 911 first, then tell your physician |
Across the trials, investigators reported no safety concerns from clinical or laboratory assessments. Long-term data does not exist. The full detail is in ARA-290 side effects.
ARA-290 for Women
Where ARA-290 stands with the FDA
As of the FDA's 14 May 2026 update, cibinetide (ARA-290) is in Category 3 of substances nominated for the 503A bulks list, "Bulk Drug Substances Nominated Without Adequate Support." That is a paperwork category, not a safety finding. It is not on the Category 2 list of substances that raise significant safety risks. It is prescription-only, compounded, and not FDA approved.
ARA-290 for Women
How Pepti supplies ARA-290
| Product | What is in it | Typical directions | Price |
|---|---|---|---|
| ARA-290 | 5 mL multi-dose vial, 2 mg/mL (10 mg ARA-290) | 0.25 mL (25 units) subcutaneously once daily Monday through Friday; 0.5 mg per dose, 20 doses | $219/mo |
Twenty weekday doses is about four weeks, the same treatment length the human trials studied; refills run every 28 days, one vial per fill. The arithmetic is in ARA-290 dosage. Your physician sets your directions after reviewing your intake, and they are printed on the vial.
The price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. Pepti is cash-pay and does not bill insurance. The vial arrives as a ready-to-use multi-dose solution with sterile syringes and alcohol prep pads, shipped refrigerated with ice packs.
ARA-290 for Women
Where to get ARA-290 prescribed
ARA-290 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for identity, purity, sterility or concentration. The prescription route:
- Complete a free online intake covering your history, pregnancy or breastfeeding status, your medications (including any hormone therapy or glucose-lowering medication), and what you want help with.
- A physician licensed in your state reviews it, usually within 24 hours.
- If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
- It ships refrigerated with your directions printed on the vial.
- Your care team stays reachable for questions and side effects.
Step by step: how to get ARA-290 prescribed online.
References
What this is based on.
References
- Dahan A, Dunne A, Swartjes M et al.. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density · Mol Med (2013) · PMID 24136731
- Heij L, Niesters M, Swartjes M et al.. Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study · Mol Med (2012) · PMID 23168581
- Brines M, Patel NS, Villa P et al.. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin · Proc Natl Acad Sci U S A (2008) · PMID 18676614
- Swartjes M, Morariu A, Niesters M et al.. ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice · Anesthesiology (2011) · PMID 21873879
- Swartjes M, van Velzen M, Niesters M et al.. ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response · Mol Pain (2014) · PMID 24529189
- van Velzen M, Heij L, Niesters M et al.. ARA 290 for treatment of small fiber neuropathy in sarcoidosis · Expert Opin Investig Drugs (2014) · PMID 24555851
- Brines M, Dunne AN, van Velzen M et al.. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes · Mol Med (2015) · PMID 25387363
- Cerit H, Veer IM, Dahan A et al.. Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action · Eur Neuropsychopharmacol (2015) · PMID 26431906
- Dahan A, Brines M, Niesters M et al.. Targeting the innate repair receptor to treat neuropathy · Pain Rep (2016) · PMID 29392190
- Culver DA, Dahan A, Bajorunas D et al.. Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain · Invest Ophthalmol Vis Sci (2017) · PMID 28475703
- Thomas A, Knoop A, Schänzer W et al.. Characterization of in vitro generated metabolites of selected peptides <2 kDa prohibited in sports · Drug Test Anal (2017) · PMID 28941172
- Brines M, Culver DA, Ferdousi M et al.. Corneal nerve fiber size adds utility to the diagnosis and assessment of therapeutic response in patients with small fiber neuropathy · Sci Rep (2018) · PMID 29549285
Citations are provided for educational purposes. They do not constitute medical advice. Always discuss any peptide protocol with your prescribing physician.
Common questions
ARA-290 for Women, answered.
It has not been studied in women specifically. Its trials were in adults with sarcoidosis or type 2 diabetes and small-fibre neuropathy, and none reports women separately.
No. It is not used in pregnancy or while breastfeeding, because safety data is absent.
Nothing in the live research looks at ARA-290 and fertility. Raise it with your physician before starting.
It is not a hormone and is not described to act on any hormone axis or the menstrual cycle.
No interaction is described, but no study has looked at the combination and there is no established interaction list. List every hormone product on your intake.
No study has looked at that. Its research is in small-fibre neuropathy in sarcoidosis and type 2 diabetes.
No. It was engineered not to act on red cell production, and the trials confirmed no effect on blood counts. It is not a treatment for anaemia.
No study in the live research has tested it in fibromyalgia. The human trials were in sarcoidosis and type 2 diabetes only.
The same as for anyone: mostly injection-site redness, soreness or bruising. The trials reported no safety concerns. Facial or throat swelling or trouble breathing needs 911.
At Pepti, ARA-290 is $219 a month, all-in, covering medication, physician review, refill management and shipping.
No. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account. The free assessment goes to a physician licensed in your state. A consultation does not guarantee a prescription.
Next step
See what a physician recommends for you.
A licensed physician in your state reviews your intake and decides what is appropriate. A consultation does not guarantee a prescription.